EF Hutton analyst Elemer Piros lowered the firm’s price target on Atai Life Sciences to $15 from $23 and reiterates a Buy rating on the shares. The company reported inconsequential data for R-ketamine when tested in treatment-resistant depression, Piros tells investors in a research note. The analyst says that while Atai has a "very significant pipeline," he discounts the stock’s valuation by 50% compared to a universe of peer companies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATAI:
- Atai Life Sciences says Phase 2a trial of PCN-101 did not meet primary endpoint
- atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
- Oregon becomes first U.S. state to legalize ‘magic’ mushrooms, NYT says
- Here’s What You Missed in Cannabis, Psychedelics This Week
- atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101